Aligos Therapeutics Announces $92M Private Placement Financing
Portfolio Pulse from Happy Mohamed
Aligos Therapeutics, Inc. (NASDAQ:ALGS) has announced a private placement financing expected to generate $92 million in gross proceeds. The funds will be used to advance its portfolio of drug candidates, including its Phase 2a NASH, ALG-055009 study, and its CAM-E candidate, ALG-000184. The financing is expected to extend the company's cash runway through the end of 2025.
October 23, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aligos Therapeutics' private placement financing is expected to generate $92 million, which will be used to advance its drug candidates and extend its cash runway through 2025.
The private placement financing will provide Aligos Therapeutics with the necessary funds to advance its drug candidates, which is a positive development for the company. This is likely to be viewed favorably by investors, potentially leading to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100